Canaccord analyst William Maughan raised the firm’s price target on BioNTech to $203 from $191 and keeps a Buy rating on the shares. The analyst said we think that its shares remain undervalued on the COVID opportunity alone. And with a steadily advancing oncology pipeline poised to potentially add value and several infectious disease opportunities with data in 2023, there is room for additional upside.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BNTX: